This is one of the strangest biotech reactions of the week. Moderna's personalised cancer vaccine, intismeran, combined with Merck's Keytruda showed in more than 1,100 melanoma patients: 42% lower risk of recurrence or death 38% lower risk of distant metastasis or death No new safety signals Those sound like excellent Phase 3 results. Yet MRNA collapsed roughly 17.6%, briefly touching $183 before recovering toward $200. So what went wrong? I think the answer is simple: The science beat the control arm. It did not beat the market's expectations. 🟢 WHAT THE TRIAL ACTUALLY PROVED The biggest positive is not merely the 42% number. Moderna has now taken personalised mRNA cancer therapy through a large Phase 3 study and demonstrated meaningful clinical benefit. That matters because the entire po

It depends on your risk tolerance: conservative investors should rotate to Merck, while high-conviction traders should wait for the full Phase 3 dataset. Moderna’s 14% pop reflects a short-covering squeeze and repricing of pipeline optionality following Wolfe Research’s upgrade to Peer Perform. However, holding at $158+ requires high conviction: the $9.2B peak sales figure is an unadjusted wall-street model assumption across multiple indications—not active product orders—and must be split 50/50 with partner Merck. Furthermore, Moderna's trailing twelve-month revenue has declined 27.6% to $2.23B, and detailed numerical Phase 3 INTerpath-001 data (including overall survival and hazard ratios) has not yet been peer-reviewed or fully presented.

While the $9.2B peak sales model for intismeran provides strong long-term validation for Moderna’s mRNA platform beyond COVID-19, chasing a 14% single-day pop driven by a broker upgrade from Underperform to Neutral carries high near-term risk. Without published Phase 3 trial specifics or signed commercial contracts, current pricing reflects speculative future potential while LTM revenue remains down 27.6% y/y at $2.23B. The safer play is rotating into Merck, which split-funds the therapy and provides immediate downside protection via Keytruda cash flows, or simply waiting for detailed clinical data before building a core position in Moderna.

Interesting... interesting...

The key takeaway is that money has not simply waited for Nvidia’s earnings—it has rotated around them. AMD, Nebius and other names rallied on company-specific catalysts, suggesting investors are selectively pricing opportunities rather than making a broad semiconductor bet. That matters because Nvidia’s results may reset the entire queue. With expectations already extremely high, a simple earnings beat may no longer be enough; investors will likely focus on guidance, AI spending sustainability and whether Nvidia’s financing relationships create additional risk. In my view, Tuesday’s moves are less a sign of money abandoning Nvidia than a sign that investors are reducing event risk while searching for the next layer of AI beneficiaries. Once Nvidia reports, capital could quickly rotate aga

Hello. Nvidia does not report until after tonight's US close. Not one of Tuesday's five biggest gainers rose because of it. $NVIDIA(NVDA)$ itself closed up 2.19 per cent at US$213.05, snapping a seven-session losing streak, and added 0.29 per cent after hours. The indices rose with it: $S&P 500(.SPX)$ up 0.32 per cent and $Invesco QQQ(QQQ)$ 0.62 per cent, with coverage noting $Dow Jones(.DJI)$ had posted a third straight triple-digit gain. On the results themselves, the options market is pricing a swing of about US$280 billion in market value, with anothe

I would wait for the data. Moderna’s rally shows the market is shifting from a short-covering story towards assigning real value to intismeran, and a potential $9.2bn peak-sales opportunity would clearly transform the company’s outlook. But peak sales are still a model, not realised demand. With LTM revenue around $2.23bn and declining, paying up after another 14% jump leaves little room for disappointing efficacy, regulatory delays or slower commercial adoption. Merck offers the more diversified route to the same oncology opportunity, but with less upside sensitivity if intismeran succeeds spectacularly. For Moderna, I would rather miss the first part of the move and add after stronger clinical data validate the revenue thesis. At $158+, evidence matters more than analyst targets.

I don't know if this is kind of manipulation and maybe this is just a hype?

Manipulation I think??

Moderna’s 2026 transformation is bigger than a one-day stock rally. The 177% surge followed by a 23.6% pullback shows how aggressively markets are repricing its mRNA platform. The real catalyst is mRNA-4157’s Phase 3 success, potentially opening a multibillion-dollar personalized cancer-vaccine market. Yet investors should separate platform potential from valuation reality. Moderna still burns billions annually, while COVID revenue continues to decline. At $133, expectations for rapid oncology commercialization are already high. The bull case is compelling: successful cancer-vaccine approval could create a new growth engine beyond respiratory vaccines. The bear case is equally clear: manufacturing complexity, competition and delayed profitability could expose the stock to another sharp co

The Coming-of-Age from "Pandemic Stock" to "mRNA Platform Titan" August 21, 2026 On August 19, $Moderna, Inc.(MRNA)$ 's stock price skyrocketed 177% in a single session, surging from $62.96 to $174.38. On August 20, it plummeted 23.6% to $133.32. Over the two days, the cumulative gain still stood at 111.7%, but $16.4 billion in market cap evaporated in a single day. This roller-coaster was not driven by a fundamental reversal, but rather by violent repricing of the mRNA platform's value by capital markets. For Moderna, August 2026 marks its official coming-of-age—from a "COVID beneficiary stock" to a "diversified mRNA platform company." For the XBI and broader biotech sector, it serves as a textbook demonstration of "sentiment contagion" and "risk

It will be interesting to see the paper for $Moderna, Inc.(MRNA)$ and $Merck(MRK)$ to dive in the details on how good the survival data is. No OS data is also something to take note of.

What will 500 tiger coins get me?: the “manifesting” million dollar blanket/throw rug! Hint hint[Miser]

What a victory for $Moderna, Inc.(MRNA)$ ! Hopefully will Medicare & Healthcare associated costs will be affordable.

Disclaimer: Nothing I say or post should be considered financial advice. Please do your own due diligence before making any investment decisions.‌ $Moderna, Inc.(MRNA)$ $Merck(MRK)$ Merk and Moderna absolutely ripped on the news of discovery of an antibody that have a breakthrough in cancer therapy. Its been a long time since we last saw such a huge upside move for biotech companies. I myself is a Registered Nurse by training. So seeing a medical company doing well warms my heart. However, investors who are looking to ride this bullish wave be careful. What goes up usually will come down. When it’s going to retrace nobody knows. So set your goals and stick to the plan if you are trading these stocks. @Paws

If I had to choose, I’d rather own the “toll collector” in the memory cycle than the companies forced to absorb higher costs. The key point is that rising memory prices are no longer an isolated semiconductor story. They are spreading downstream—from smartphones to GPUs and AI infrastructure. Xiaomi’s adjusted profit fell 42.6% year over year as higher memory costs squeezed margins, while Intel’s Arc Pro B70 prices have reportedly risen sharply in some markets. That tells me pricing power currently sits upstream. But I would not blindly chase memory stocks after their huge run. The better strategy is to own the suppliers with strong pricing power, healthy balance sheets and long-term AI demand, while avoiding companies whose margins are being compressed. In short: follow the money upstrea

I would not chase Moderna at $174.38. I would rank the three choices: 1. Merck: best risk/reward 2. Wait for full data: best disciplined approach 3. Moderna: highest upside, but highest valuation risk The Phase 3 result is genuinely important. INTerpath-001 hit both recurrence-free survival and distant-metastasis-free survival, validating the personalised neoantigen approach in a pivotal trial.  But Moderna has already repriced the success very aggressively. The market is now capitalising not merely the melanoma indication, but the possibility that this becomes a platform across multiple solid tumours. That is where I would be cautious. Full hazard ratios, subgroup consistency, overall survival, durability, manufacturing economics and regulatory details are still needed. Reuters speci

Hello. The long end, which had been pressing on everything for three days, got held down on Wednesday. The 30-year Treasury yield first set a 19-year high intraday, then turned back after the US Treasury said it would at least double the size of its liquidity support buybacks in 10- to 30-year securities. The 30-year fell as much as 9 basis points to 5.19 per cent, closed near 5.20 per cent, and is down to 5.18 per cent today. But technology did not come back. $SPDR S&P 500 ETF Trust(SPY)$ closed up 0.21 per cent and $Dow Jones(.DJI)$ 0.22 per cent, and most of that came from healthcare while tech kept being sold. One headline put it plainly: the tech sell-off resumed an